CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
Sakakibara, Keiichi, Saito, Naoya, Sato, Takuji, Suzuki, Atsushi, Hasegawa, Yoko, Friedman, Jonathan M., Kufe, Donald W., VonHoff, Daniel D., Iwami, Tadahiko, Kawabe, Takumi
Published in Blood (06.10.2011)
Published in Blood (06.10.2011)
Get full text
Journal Article
Abstract 658: CBS9106 is a novel low toxic reversible oral CRM1 inhibitor with CRM1 degrading activity
Sakakibara, Keiichi, Saito, Naoya, Sato, Takuji, Suzuki, Atsushi, Hasegawa, Yoko, Friedman, Jonathan M., Suganuma, Masashi, Kufe, Donald W., VanHoff, Daniel D., Iwami, Tadahiko, Kawabe, Takumi
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Get full text
Journal Article
N-2 Acetylation of 2′-deoxyguanosine by coffee mutagens, methylglyoxal and hydrogen peroxide
Nukaya, Haruo, Iwami, Tadahiko, Ishida, Hitoshi, Tsuji, Kuniro, Suwa, Yoshihide, Wakabayashi, Keiji, Nagao, Minako, Sugimura, Takashi, Kosuge, Takuo
Published in Mutation research (01.12.1990)
Published in Mutation research (01.12.1990)
Get full text
Journal Article